Chronically ill patients in last years of life account for 32% of total Medicare spending.
By: John E. Schiller, Esq.
Our healthcare delivery and finance system spends an enormous amount of money providing medical care (not palliative care) in the last year of life. Although it is the third rail of healthcare reform, it must be discussed. Policymakers do us a disservice by pretending that it’s an issue that can be put aside. Unfortunately, chants of death panels all but silenced any meaningful effort to address this important topic.
By all accounts, a meaningful portion of healthcare spending is for care of some kind during the last year of life. In fact, according to the Dartmouth Atlas of Care, patients with chronic illness in their last two years of life account for about 32% of total Medicare spending. This is only one of many studies that documents the large expenditures being covered for care of patients in their final days.
These numbers scream for a national dialogue about what medical care is owed to people who have reached an age when they face chronic medical maladies that require expensive treatment and often involve hospitalization and secondary illnesses, such as infections. What care is given in the last year(s) of life; who should decide what care is appropriate; how such care should be delivered; and who should pay for it are all questions that policymakers and citizens need to think about and act on if we are to strike a fair balance in end-of-life care.
It’s wrong for the aged to die in hospital beds after suffering medical interventions that, in the end, cannot stop the inevitable. Or worse, die from painful infections picked up in a hospital.
For most people, the cost of end-of-life care for the elderly is paid for by a third party, and there is no real financial cost to the patient or his or her family. Given the enormous pull of wanting the patient to stay alive, no effort is spared-whether it makes the patient more comfortable or not.
Health reform’s effect
Although the Affordable Care Act does establish palliative care as an essential health benefit that must be covered by all insurance plans subject to the law, each state can decide how to meet this requirement and how, or if hospice will be a covered service. This presents a good opportunity for stakeholders in each state to address a number of important policy issues including the following:
Many studies and reports contain not only objective data that must be considered, but also a host of important subjective observations and suggestions. End-of-life care in other countries offers helpful insights that are also worthy of study. Hopefully this subject will get the attention it deserves and policies will be refined and developed that will move our country forward to a more sensible, consistent, compassionate and cost-effective approach to end-of-life care.
Schiller is a partner and head of the Health Law Practice Group at Cleveland-based Walter | Haverfield LLP.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Inflation Reduction Act: Reforms to Patient Cost-Sharing
September 18th 2023Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Read More
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More
Talking PIE, the Act, Before Thanksgiving
November 23rd 2022AMCP CEO Susan A. Cantrell spoke with Managed Healthcare Executive® about Preapproval Information Exchange (PIE) Act of 2022, which would allow drug manufacturers to share information about a drug with payers before the drug is approved. Cantrell says passage of the PIE Act would speed up patient access to new medications.
Read More
Inflation Reduction Act and the Impact on Pharmaceutical Pricing and Investment Decisions
November 21st 2022The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.
Read More